<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18250">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813110</url>
  </required_header>
  <id_info>
    <org_study_id>PRONOVA</org_study_id>
    <nct_id>NCT01813110</nct_id>
  </id_info>
  <brief_title>Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation</brief_title>
  <acronym>PRONOVA</acronym>
  <official_title>Effects of a Prescription Omega-3 Fatty Acid Concentrate in a Placebo-controlled Trial of Human Endotoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the marine omega-3 fatty acids can attenuate
      inflammatory responses to endotoxin challenge.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in C reactive protein (CRP)</measure>
    <time_frame>24 hours post endotoxin administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in blood levels of CRP at 24 hours post endotoxin administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostaglandin J3</measure>
    <time_frame>7 days post endotoxin challenge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in plasma levels of prostaglandin J3 resulting from omega-3 supplementation and induced inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Inflammatory Responses</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical olive oil capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 g prescription omega-3 concentrate</intervention_name>
    <description>4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Lovaza</other_name>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men between the ages of 20 and 45.

          2. BMI ≥20 and ≤30

          3. Participants who are able to give written informed consent and willing to comply with
             all study-related procedures.

          4. Any race or ethnic background is acceptable

          5. Non-smoking

        The specific exclusion criteria are:

          1. Previous history of vasovagal reactions or unprovoked fainting (I.e. fainting as a
             result of prolonged standing, exercise)

          2. Resting heart rate &lt; 55 bpm

          3. History of atherosclerotic cardiovascular disease, including coronary disease,
             cerebrovascular disease, or peripheral vascular disease

          4. History of diabetes mellitus (and/or a fasting glucose &gt;126 mg/dL at screening)

          5. Chronic anti-inflammatory medication use or treatment with aspirin, NSAIDs, COX-2
             inhibitors; steroids or any immunomodulatory therapy 2 weeks prior to the screening
             visit

          6. Self-reported history of allergy to fish

          7. History of a non-skin malignancy within the previous 5 years

          8. Renal insufficiency as defined by creatinine outside of lab defined normal range at
             Screening Visit

          9. History of liver disease or abnormal LFTs (AST, ALT, Alk. Phos., GGT &gt; 1.5x ULN;
             bilirubin &gt; 2x ULN) at Screening Visit

         10. Total white blood cell count less than or equal to 3.0 THO/uL

         11. Hemoglobin less than 11.0 g/dL

         12. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory
             condition or minor active infection

         13. Self-reported history of HIV positive

         14. Participants who have undergone any organ transplant

         15. Individuals who currently use tobacco products or have done so in the previous 30
             days.

         16. Participants who are unwilling to discontinue use of nutritional supplements, herbs
             or vitamins unless approved by study staff.

         17. Participants who are unwilling to eliminate omega-3 fatty acid (EPA + DHA)
             supplements and/or fortified food, or have a usual intake of high omega-3 fish (tuna
             and other non-fried fish) &gt; 2 servings per week

         18. Elevated blood pressure (BP &gt; 159/99) or use of any anti-hypertensive medications.

         19. Latex allergy

         20. Unwillingness to refrain from blood donation for 2 months prior to and following
             endotoxin administration

         21. Any medical condition or abnormal laboratory value that is judged clinically
             significant by an investigator

         22. Inability to take study capsules

         23. History of severe, repeated headaches

         24. History of migraine

         25. Medical condition that causes severe nausea or vomiting

         26. Low resting blood pressure (SBP &lt; 90 mmHg)

         27. History of atrial fibrillation/flutter

         28. Abnormal coagulation parameters (platelet count, prothrombin time with INR),
             documented coagulation abnormality, or use of anticoagulant medication

         29. High LDL-C (&gt; or = 160 mg/dL)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann C. Skulas-Ray, PhD</last_name>
    <phone>814-863-8056</phone>
    <email>aus164@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer A. Fleming, MS, RD</last_name>
    <phone>814-863-8056</phone>
    <email>jas58@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>omega-3</keyword>
  <keyword>fish oil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
